Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington disease and amyotrophic lateral sclerosis throw a heavy burden on families and society. Related scientific researches make tardy progress. One reason is that the known pathogeny is just the tip of the iceberg. Another reason is that various physiological barriers, especially blood-brain barrier (BBB), hamper effective therapeutic substances from reaching site of action. Drugs in clinical treatment of neurodegenerative diseases are basically administered orally. And generally speaking, the brain targeting efficiency is pretty low. Nano-delivery technology brings hope for neurodegenerative diseases. The use of nanocarriers encapsulating molecules such as peptides and genomic medicine may enhance drug transport through the BBB in neurodegenerative disease and target relevant regions in the brain for regenerative processes. In this review, we discuss BBB composition and applications of nanocarriers -liposomes, nanoparticles, nanomicelles and new emerging exosomes in neurodegenerative diseases. Furthermore, the disadvantages and the potential neurotoxicity of nanocarriers according pharmacokinetics theory are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Ying, W., Riopel, M., Bandyopadhyay, G., Dong, Y., Birmingham, A., Seo, J. B., Ofrecio, J. M., Wollam, J., Hernandez-Carretero, A., Fu, W., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.035 · Cited by 1,191 · cited 2×
“[106] Ying W , Riopel M , Bandyopadhyay G , et al.”
BackgroundGurr, J.-R., Wang, A. S. S., Chen, C.-H., & Jan, K.-Y. (2005) · Toxicology · doi:10.1016/j.tox.2005.05.007 · Cited by 1,022
Kumar, D. K. V., Choi, S. H., Washicosky, K. J., Eimer, W. A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L. E., Tanzi, R. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1059 · Cited by 971
Kojima, R., Bojar, D., Rizzi, G., Hamri, G. C.-E., El-Baba, M. D., Saxena, P., Ausländer, S., Tan, K. R., & Fussenegger, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03733-8 · Cited by 748
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Exosomes are natural carriers of exogenous siRNA to human cells in vitro
Shtam, T. A., Kovalev, R. A., Varfolomeeva, E. Y., Makarov, E. M., Kil, Y. V., & Filatov, M. V. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-88 · Cited by 499
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
Didiot, M.-C., Hall, L. M., Coles, A. H., Haraszti, R. A., Godinho, B. M., Chase, K., Sapp, E., Ly, S., Alterman, J. F., Hassler, M. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.126 · Cited by 483
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier
Matsumoto, J., Stewart, T., Banks, W. A., & Zhang, J. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170913164738 · Cited by 267
Shah, S. A., Yoon, G. H., Chung, S. S., Abid, M. N., Kim, T. H., Lee, H. Y., & Kim, M. O. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.23 · Cited by 206 · cited 2×
“[76] Shah SA , Yoon GH , Chung SS , et al.”
BackgroundExosome-Based Delivery of miR-124 in a Huntington’s Disease Model
Lee, S.-T., Im, W., Ban, J.-J., Lee, M., Jung, K.-H., Lee, S. K., Chu, K., & Kim, M. (2017) · Journal of Movement Disorders · doi:10.14802/jmd.16054 · Cited by 164
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., Mauri, M., Cagnotto, A., Colombo, L., Fiordaliso, F., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0284-14.2014 · Cited by 162
Pardridge, W. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1042364 · Cited by 159 · cited 1×
“For example Alvarez-Erviti research [16] used argeted exosomes to cross BBB.”
MethodLazar, A. N., Mourtas, S., Youssef, I., Parizot, C., Dauphin, A., Delatour, B., Antimisiaris, S. G., & Duyckaerts, C. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.004 · Cited by 149
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114 · cited 2×
“[82] Wadghiri YZ , Li J , Wang J , et al.”
BackgroundChen, T., Li, C., Li, Y., Yi, X., Wang, R., Lee, S. M.-Y., & Zheng, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01171 · Cited by 89
Baker, S. K., Chen, Z.-L., Norris, E. H., Revenko, A. S., MacLeod, A. R., & Strickland, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811172115 · Cited by 68
Multifunctional LUV Liposomes Decorated for BBB and Amyloid Targeting. A. In Vitro Proof-of-Concept
Papadia, K., Markoutsa, E., Mourtas, S., Giannou, A. D., La Ferla, B., Nicotra, F., Salmona, M., Klepetsanis, P., Stathopoulos, G. T., & Antimisiaris, S. G. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.019 · Cited by 40
Cited by
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system
Liu, H., Su, Y.-Y., Jiang, X.-C., & Gao, J.-Q. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01252-0 · Cited by 302
Self-citationNeuroprotective Natural Products for Alzheimer’s Disease
Chen, X., Drew, J., Berney, W., & Lei, W. (2021) · Cells · doi:10.3390/cells10061309 · Cited by 236
Rahman, M. H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T. T., Akter, R., Jeong, Y. J., Goh, S. H., Kim, C.-S., & Lee, K.-J. (2021) · Molecules · doi:10.3390/molecules26175327 · Cited by 182
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Metadata
- Authors
- Niu, X., Chen, J., & Gao, J.
- Venue
- Asian Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 14
- Issue
- 5
- Pages
- 480-496
- ISSN
- 1818-0876 (ISSN-L)
- OpenAlex
- W2896954918
- Cited by
- 190
- References
- 27
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.